Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2007 2
2008 2
2009 2
2010 1
2011 3
2012 6
2013 4
2014 2
2015 7
2016 3
2017 8
2018 3
2019 8
2020 7
2021 10
2022 8
2023 7
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

78 results

Results by year

Filters applied: . Clear all
Page 1
Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer.
Goodwin CM, Waters AM, Klomp JE, Javaid S, Bryant KL, Stalnecker CA, Drizyte-Miller K, Papke B, Yang R, Amparo AM, Ozkan-Dagliyan I, Baldelli E, Calvert V, Pierobon M, Sorrentino JA, Beelen AP, Bublitz N, Lüthen M, Wood KC, Petricoin EF, Sers C, McRee AJ, Cox AD, Der CJ. Goodwin CM, et al. Among authors: pierobon m. Cancer Res. 2023 Jan 4;83(1):141-157. doi: 10.1158/0008-5472.CAN-22-0391. Cancer Res. 2023. PMID: 36346366 Free PMC article. Clinical Trial.
The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.
Hallin J, Engstrom LD, Hargis L, Calinisan A, Aranda R, Briere DM, Sudhakar N, Bowcut V, Baer BR, Ballard JA, Burkard MR, Fell JB, Fischer JP, Vigers GP, Xue Y, Gatto S, Fernandez-Banet J, Pavlicek A, Velastagui K, Chao RC, Barton J, Pierobon M, Baldelli E, Patricoin EF 3rd, Cassidy DP, Marx MA, Rybkin II, Johnson ML, Ou SI, Lito P, Papadopoulos KP, Jänne PA, Olson P, Christensen JG. Hallin J, et al. Among authors: pierobon m. Cancer Discov. 2020 Jan;10(1):54-71. doi: 10.1158/2159-8290.CD-19-1167. Epub 2019 Oct 28. Cancer Discov. 2020. PMID: 31658955 Free PMC article.
P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia.
Lin KH, Rutter JC, Xie A, Killarney ST, Vaganay C, Benaksas C, Ling F, Sodaro G, Meslin PA, Bassil CF, Fenouille N, Hoj J, Washart R, Ang HX, Cerda-Smith C, Chaintreuil P, Jacquel A, Auberger P, Forget A, Itzykson R, Lu M, Lin J, Pierobon M, Sheng Z, Li X, Chilkoti A, Owzar K, Rizzieri DA, Pardee TS, Benajiba L, Petricoin E, Puissant A, Wood KC. Lin KH, et al. Among authors: pierobon m. Nat Cancer. 2022 Jul;3(7):837-851. doi: 10.1038/s43018-022-00394-x. Epub 2022 Jun 6. Nat Cancer. 2022. PMID: 35668193 Free PMC article.
Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer.
Bryant KL, Stalnecker CA, Zeitouni D, Klomp JE, Peng S, Tikunov AP, Gunda V, Pierobon M, Waters AM, George SD, Tomar G, Papke B, Hobbs GA, Yan L, Hayes TK, Diehl JN, Goode GD, Chaika NV, Wang Y, Zhang GF, Witkiewicz AK, Knudsen ES, Petricoin EF 3rd, Singh PK, Macdonald JM, Tran NL, Lyssiotis CA, Ying H, Kimmelman AC, Cox AD, Der CJ. Bryant KL, et al. Among authors: pierobon m. Nat Med. 2019 Apr;25(4):628-640. doi: 10.1038/s41591-019-0368-8. Epub 2019 Mar 4. Nat Med. 2019. PMID: 30833752 Free PMC article.
Concurrent Inhibition of IGF1R and ERK Increases Pancreatic Cancer Sensitivity to Autophagy Inhibitors.
Stalnecker CA, Grover KR, Edwards AC, Coleman MF, Yang R, DeLiberty JM, Papke B, Goodwin CM, Pierobon M, Petricoin EF, Gautam P, Wennerberg K, Cox AD, Der CJ, Hursting SD, Bryant KL. Stalnecker CA, et al. Among authors: pierobon m. Cancer Res. 2022 Feb 15;82(4):586-598. doi: 10.1158/0008-5472.CAN-21-1443. Cancer Res. 2022. PMID: 34921013 Free PMC article.
Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer.
Hobbs GA, Baker NM, Miermont AM, Thurman RD, Pierobon M, Tran TH, Anderson AO, Waters AM, Diehl JN, Papke B, Hodge RG, Klomp JE, Goodwin CM, DeLiberty JM, Wang J, Ng RWS, Gautam P, Bryant KL, Esposito D, Campbell SL, Petricoin EF 3rd, Simanshu DK, Aguirre AJ, Wolpin BM, Wennerberg K, Rudloff U, Cox AD, Der CJ. Hobbs GA, et al. Among authors: pierobon m. Cancer Discov. 2020 Jan;10(1):104-123. doi: 10.1158/2159-8290.CD-19-1006. Epub 2019 Oct 24. Cancer Discov. 2020. PMID: 31649109 Free PMC article.
RHOAL57V drives the development of diffuse gastric cancer through IGF1R-PAK1-YAP1 signaling.
Schaefer A, Hodge RG, Zhang H, Hobbs GA, Dilly J, Huynh MV, Goodwin CM, Zhang F, Diehl JN, Pierobon M, Baldelli E, Javaid S, Guthrie K, Rashid NU, Petricoin EF, Cox AD, Hahn WC, Aguirre AJ, Bass AJ, Der CJ. Schaefer A, et al. Among authors: pierobon m. Sci Signal. 2023 Dec 19;16(816):eadg5289. doi: 10.1126/scisignal.adg5289. Epub 2023 Dec 19. Sci Signal. 2023. PMID: 38113333 Free PMC article.
Phosphorylation, Signaling, and Cancer: Targets and Targeting.
Marmiroli S, Fabbro D, Miyata Y, Pierobon M, Ruzzene M. Marmiroli S, et al. Among authors: pierobon m. Biomed Res Int. 2015;2015:601543. doi: 10.1155/2015/601543. Epub 2015 Oct 21. Biomed Res Int. 2015. PMID: 26576427 Free PMC article. No abstract available.
Functional and biological heterogeneity of KRASQ61 mutations.
Huynh MV, Hobbs GA, Schaefer A, Pierobon M, Carey LM, Diehl JN, DeLiberty JM, Thurman RD, Cooke AR, Goodwin CM, Cook JH, Lin L, Waters AM, Rashid NU, Petricoin EF 3rd, Campbell SL, Haigis KM, Simeone DM, Lyssiotis CA, Cox AD, Der CJ. Huynh MV, et al. Among authors: pierobon m. Sci Signal. 2022 Aug 9;15(746):eabn2694. doi: 10.1126/scisignal.abn2694. Epub 2022 Aug 9. Sci Signal. 2022. PMID: 35944066 Free PMC article.
78 results